Levels of mRNA for dopaminergic receptor D₅ in circulating lymphocytes may be associated with subsequent response to interferon-β in patients with multiple sclerosis

Marco Cosentino; Mauro Zaffaroni; Franca Marino

doi:10.1016/j.jneuroim.2014.10.009

Levels of mRNA for dopaminergic receptor D₅ in circulating lymphocytes may be associated with subsequent response to interferon-β in patients with multiple sclerosis

J Neuroimmunol. 2014 Dec 15;277(1-2):193-6. doi: 10.1016/j.jneuroim.2014.10.009. Epub 2014 Oct 31.

Authors

Marco Cosentino¹, Mauro Zaffaroni², Franca Marino³

Affiliations

¹ Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy. Electronic address: marco.cosentino@uninsubria.it.
² Multiple Sclerosis Center, Hospital 'S. Antonio Abate', Gallarate, VA, Italy.
³ Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy.

PMID: 25468276
DOI: 10.1016/j.jneuroim.2014.10.009

Abstract

Interferon (IFN)-β is among the first-line therapies for multiple sclerosis (MS), however the clinical response varies among individuals, and early identification of responders and non-responders would be of critical importance. Here we show that before treatment circulating lymphocytes of MS patients who will respond to IFN-β have higher mRNA levels for the D1-like dopaminergic receptor (DR) D5 in comparison to cells from those who will not respond. Lymphocyte DR D5 is reduced in MS and IFN-β restores their expression and responsiveness. DR D5 mRNA levels in circulating lymphocytes might represent an early marker of response to IFN-β in MS patients.

Keywords: Dopaminergic receptors; Interferon beta; Lymphocytes; Multiple sclerosis; Tyrosine hydroxylase; β(2)-Adrenoceptors.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies / pharmacology
Female
Humans
Immunologic Factors / pharmacology*
Immunologic Factors / therapeutic use
Interferon-beta / immunology
Interferon-beta / pharmacology*
Interferon-beta / therapeutic use
Lymphocytes / drug effects*
Lymphocytes / metabolism*
Male
Middle Aged
Multiple Sclerosis / drug therapy
Multiple Sclerosis / pathology*
RNA, Messenger / metabolism*
ROC Curve
Receptors, Adrenergic, beta-2 / genetics
Receptors, Adrenergic, beta-2 / metabolism
Receptors, Dopamine D2 / genetics
Receptors, Dopamine D2 / metabolism
Receptors, Dopamine D5 / genetics*
Receptors, Dopamine D5 / metabolism
Tyrosine 3-Monooxygenase / genetics
Tyrosine 3-Monooxygenase / metabolism
Young Adult

Substances

Antibodies
Immunologic Factors
RNA, Messenger
Receptors, Adrenergic, beta-2
Receptors, Dopamine D2
Receptors, Dopamine D5
Interferon-beta
Tyrosine 3-Monooxygenase